OncoMatch/Clinical Trials/NCT05807035
Autologous Tumour Vaccine Trial
Is NCT05807035 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Radvax for solid tumor.
Treatment: Radvax — Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid cancers either as monotherapy or in combination with other standard of care agents
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: investigational agent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05807035 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify